General
impact 16
Delivering an immune therapy into tumours instead of intravenously reduces adverse effects
Delivering an immune therapy into tumours instead of intravenously reduces adverse effects Nature, Published online: 29 April 2026; doi:10.1038/d41586-026-01193-5 In people with advanced skin cancer, injecting low doses…
Why it matters
The immune community will be debating this. Pay attention to how delivering players respond in the coming weeks.